Cyclopharm eyes faster market entry for Technegas following positive US FDA meeting
Technegas is inhaled by patients and allows the diagnosis of multiple respiratory diseases via imaging and analytical software
Company
Cyclopharm Ltd
ASX:CYC
Cyclopharm, a global radiopharmaceutical industry leader, is synonymous with innovation and excellence in pulmonary care. Under the Cyclomedica banner, the company has been enabling advancements in groundbreaking lung imaging solutions since 1986 through its flagship product, Technegas®.
13 stories
Cyclopharm achieves another milestone for its Technegas technology in the US
The company’s Technegas generators produce a gas which detects pulmonary embolism.
Cyclopharm begins nuclear imaging trial to detect respiratory diseases
The company’s Technegas generators produce a gas which detects pulmonary embolism
The Carajas Copper Company to lift cash position
The Carajas Copper Company (ASX:CJC) has been granted a trading halt by the ASX, pending details of a capital raising.
Cyclopharm makes progress on U.S. clinical trial
Radiopharmaceutical company Cyclopharm Ltd (ASX:CYC) has successfully completed the first stage of its U.S. FDA clinical trial program for Technegas generators.